Role of the JAK/STAT pathway in a streptozotocin-induced diabetic retinopathy mouse model
- 23 May 2022
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 260 (11) , 3553-3563
Abstract
Purpose The Janus tyrosine kinase and signal transducers and activators of transcription (JAK/STAT) pathway is involved in vascular endothelial growth factor (VEGF) expression, but the role of this pathway in diabetic retinopathy (DR) remains unclear. We investigated the role of the JAK/STAT pathway on DR and VEGF expression using a streptozotocin (STZ)-induced DR mouse model. Methods Cultured ARPE-19 cells were exposed to high-glucose conditions and treated with JAK/STAT inhibitors (JAK inhibitor I [JAKiI], tofacitinib, STAT3 inhibitor [STAT3i]) for 48 h. Reverse-transcription polymerase chain reaction, western blotting, and enzyme-linked immunosorbent assay were used to investigate p-JAK/STAT and VEGF expression. Diabetes was induced by intraperitoneal injection of STZ (50 mg/kg) in C57BL/6 mice for 5 days. DR development was evaluated every 4 weeks. JAK/STAT inhibitors were administered for 8 weeks. Immunofluorescence was used to measure the activation status of the JAK/STAT pathway and VEGF production in the retinal tissue. Results In ARPE-19 cells exposed to high-glucose conditions, the mRNA and secretory protein levels of VEGF, p-JAK1, p-JAK2, p-STAT3, and p-STAT5 levels were significantly increased. Treatment with JAKiI, tofacitinib, and STAT3i significantly suppressed VEGF to basal levels at both the mRNA and secretory levels in vitro. In STZ-induced mice, retinal vascular leakage, p-JAK1, p-JAK2, p-JAK3, p-STAT3, and VEGF were significantly increased after diabetes induction. Diabetes-induced retinal vascular leakage was significantly reduced by treatment with JAKiI and tofacitinib. Increased p-JAK1 and VEGF in STZ-induced mice were significantly reduced by JAKiI (p < 0.05, p < 0.001) and tofacitinib (p < 0.001, respectively). Conclusion JAK1 may be more involved in VEGF production and DR progression in mice than JAK2, JAK3, and STAT3.Keywords
Funding Information
- Ministry of Education (NRF-2017R1D1A1B03033799)
This publication has 44 references indexed in Scilit:
- VEGF-Mediated STAT3 Activation Inhibits Retinal Vascularization by Down-Regulating Local Erythropoietin ExpressionThe American Journal of Pathology, 2012
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociNature Genetics, 2010
- Inhibition of JAK2/STAT3-Mediated VEGF Upregulation under High Glucose Conditions by PEDF through a Mitochondrial ROS Pathway In VitroInvestigative Ophthalmology & Visual Science, 2010
- The Role of Supplemental Oxygen and JAK/STAT Signaling in Intravitreous Neovascularization in a ROP Rat ModelInvestigative Ophthalmology & Visual Science, 2009
- Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase DomainsJournal of Molecular Biology, 2009
- Vascular endothelial growth factor in eye diseaseProgress in Retinal and Eye Research, 2008
- STAT4and the Risk of Rheumatoid Arthritis and Systemic Lupus ErythematosusNew England Journal of Medicine, 2007
- Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic RetinopathyJournal of Diabetes Research, 2007
- Bone morphogenetic protein‐4 enhances vascular endothelial growth factor secretion by human retinal pigment epithelial cellsJournal of Cellular Biochemistry, 2006
- The JAK/STAT signaling pathwayJournal of Cell Science, 2004